WESTBOROUGH, Mass.--(BUSINESS WIRE)--PharmaVigilant announced today they launched an electronic data capture database for a Phase 1/2 oncology study in 4 weeks for Threshold Pharmaceuticals. The clinical trial design includes three separate treatment arms examining escalating doses of TH-302, Threshold’s proprietary Hypoxia Activated Prodrug in combination with the following chemotherapeutic agents: Gemcitabine, Docetaxel or Pemetrexed. The Phase 1/2 study database design required the creation of over 50 unique case report forms and six separate CRF books to accommodate the study population. The flexibility built into the database design of this oncology trial will enable Threshold to better manage enrollment and the data collection throughout their trial without adding additional resources.
